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Abstract
Schwann cells (SCs) hold promise for spinal cord injury (SCI) repair; however, there are 
limitations for use as a lone treatment. We showed acute inhibition of the phosphatase and tensin 
homologue (PTEN) by bisperoxovanadium (bpV) was neuroprotective and enhanced function 
following cervical hemicontusion SCI. We hypothesized that combining acute bpV therapy and 
delayed SC engraftment would further improve neuroprotection and recovery after cervical SCI. 
Adult female Sprague Dawley (SD) rats were randomly sorted into 5 groups: sham, vehicle, bpV, 
SC transplantation, and bpV + SC transplantation. SCs were isolated from adult green fluorescent 
protein (GFP)-expressing SD rats (GFP-SCs). 200 g/kg bpV(pic) was administered 
intraperitoneally (i.p.) twice daily for 7 days post-SCI in bpV-treated groups. GFP-SCs (1 × 106 in 
5 μl medium) were transplanted into the lesion epicenter at the 8th day post-SCI. Forelimb 
function was tested for 10 weeks and histology was assessed. bpV alone significantly reduced 
lesion (by 40%, p<0.05) and cavitation (by 65%, p<0.05) and improved functional recovery (p 
<0.05) compared to injury alone. The combination promoted similar neuroprotection (p<0.01 vs. 
injury); however, GFP-SCs alone did not. Both SC-transplanted groups exhibited remarkable 
long-term SC survival, SMI-31+ axon ingrowth and RECA-1+ vasculature presence in the SC 
graft; however, bpV + SCs promoted an 89% greater axon-to-lesion ratio than SCs only. We 
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concluded that bpV likely contributed largely to the neuroprotective and functional benefits while 
SCs facilitated considerable host-tissue interaction and modification. The combination of the two 
shows promise as an attractive strategy to enhance recovery after SCI.
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Introduction
Schwann cells (SCs) are dynamic participants in peripheral nerve function and repair, and 
have been widely studied as a therapy for central nervous system (CNS) injury. In spinal 
cord injury (SCI) research, SCs have been studied in various contexts ranging from 
peripheral nerve transplantation (David and Aguayo, 1981; David and Aguayo, 1985; Houle, 
1991; Houle and Cote, 2013; Tom et al., 2013; Tom et al., 2009), SC-seeded channel 
engraftment (Deng et al., 2013; Deng et al., 2011; Iannotti et al., 2003; Xu et al., 1997; Xu et 
al., 1995a; Xu et al., 1995b; Xu et al., 1999) to cell suspension injection into or adjacent to 
the site of injury (Golden et al., 2007; Hu et al., 2013; Pearse et al., 2004a; Pearse et al., 
2004b; Pearse et al., 2007; Schaal et al., 2007; Siriphorn et al., 2010; Takami et al., 2002). 
Many recent studies have investigated co-transplanting SCs with other cell types including 
olfactory ensheathing cells (OECs) (Pearse et al, 2007; Takami et al, 2002) and glial 
restricted precursors (GRPs) (Hu et al, 2013). Hormonal therapy combined with SC 
transplantation has also been reported (Siriphorn et al, 2010).
The potential benefits of SCs in the injured spinal cord are many (Oudega and Xu, 2006); 
nonetheless, key limitations to SC transplantation as a single therapy for SCI persist. 
Approximately 80% of transplanted cells die by necrosis and apoptosis by the end of the 
first week after transplantation (Hill et al., 2007; Hill et al., 2006). Although SCs can 
support considerable growth of propriospinal (Iannotti et al., 2004), reticulospinal (Schaal et 
al, 2007), raphaespinal (Novikova et al., 2008) and axons of other origin, these fibers fail to 
exit the graft into caudal host tissue due to the inhibitory glial scar that encapsulates the 
contusive lesion. Delaying SC transplantation 7–10 days after injury avoids cytotoxicity of 
the acute injury and allows for cystic cavity formation for cell engraftment (Hill et al., 2007; 
Hill et al., 2006; Martin, 1996). Adding a neuroprotective therapy prior to SC transplantation 
may enhance tissue sparing, repair, and influence the SC graft following transplantation. 
Combination therapies may be necessary for advancing SC transplantation research and its 
potential as a viable clinical treatment for SCI (Bunge, 2008).
Approximately 60% of human SCI occurs at the cervical level, yet strikingly few studies 
investigated SC transplantation following cervical SCI (Schaal et al., 2007; Novikova et al., 
2008; Siriphorn et al., 2010). A better understanding of effects and benefits of cervical SC 
transplantation and new therapeutic combinations in cervical SCI models are necessary. 
Combining a pharmacological approach with SC transplantation is clinically practical due to 
ease and rapidity of administration in acutely injured patients. In addition, autologous 
transplants require several weeks to isolate, purify, and expand a sufficient number of a 
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patient’s own SCs. A neuroprotective small-molecule therapy prior to SC transplantation 
may reduce secondary damage and promote a more robust spinal response to the delayed SC 
graft.
Bisperoxovanadium (bpV) compounds are dual protein-lipid phosphatases best known for 
their potent and specific inhibition of the phosphatase and tensin homolog deleted on 
chromosome ten (PTEN) (Schmid et al., 2004), an important regulator of cell survival and 
protein synthesis among other functions. PTEN antagonizes phosphatidylinositol-3-kinase 
(PI3K) activity, limiting survival signaling through Akt and its effectors such as mammalian 
target of rapamycin (mTOR) (Nave et al., 1999), bcl-2-associated death promoter (BAD) 
(Datta et al., 1997), and glycogen synthase kinase 3β (GSK3β) (Cross et al., 1995). 
Neuroprotective and reparative effects of bpVs have been widely demonstrated in 
neurological disease and injury models (Mao et al., 2013; Song et al., 2010; Sury et al., 
2011; Yang et al., 2007; Zhang et al., 2007; Zhao et al., 2013) including SCI (Nakashima et 
al., 2008; Walker et al., 2012).
Our studies showed that bpV(pic) promoted significant neuroprotection and recovery when 
given during the first week following cervical hemicontusion SCI in rats (Walker et al., 
2012; Walker and Xu, 2014). Combining acute bpV(pic) and sub-acute SC transplantation 
may promote additional benefits by compensating for individual treatment limitations and 
complementing therapeutic strengths. We hypothesized that administering bpV(pic) acutely 
followed by subacute SC transplantation would provide benefits over either single treatment 
alone. To test this hypothesis, we employed systemic bpV(pic) treatment and transplanted 
green-fluorescent protein (GFP) transgenic SCs (GFP-SCs) for optimal histological 
identification. Using a novel forelimb functional assessment and histological analyses, our 
findings shed light on potential benefits of this combination therapy in a clinically-relevant 
cervical hemicontusive SCI model.
Materials and Methods
Schwann cell culture
Schwann cells (SCs) were purified and expanded as previously described (Morrissey et al., 
1991; Xu et al., 1995b; Xu et al., 1999). In brief, SCs were harvested from the sciatic nerves 
of transgenic homozygote green fluorescent protein (GFP)-Rosa expressing adult female 
Sprague-Dawley (SD) rats (George Smith, Temple University), followed by purification and 
expansion in culture. Cultures were > 98% pure SCs upon collection for transplantation (Xu 
et al, 1997; Xu et al, 1995b). Purified cells at passage 3 or 4 were collected for 
transplantation into the spinal lesion cavity.
Animal groups and surgical procedures
Adult female Sprague-Dawley rats (200–250 g, Harlan) (n = 34) were housed in an 
environmentally-controlled facility on a 12:12 light:dark cycle with ad libitum water and 
food access. The overall experimental design is illustrated in Fig. 1. Prior to surgery, 
animals were randomly assigned to five groups: 1) Sham (n = 6), 2) Saline-treated only 
(Veh, n = 6), 3) bpV(pic) treated (n = 6), 4) GFP-SCs (n = 7), 5) bpV(pic) + GFP-SCs (n = 
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9). The experimental groups were established based on findings reported in previous 
publications testing the effects of bpV and SCs alone (Walker et al., 2012; Wang and Xu, 
2014). In these experiments, the injury only groups and the injury plus saline group showed 
no difference. Therefore, we used the injury plus saline group as the non-treatment control. 
This helped to reduce the number of animals necessary for the present study, and allow for 
an emphasis on the comparison of the three treatment groups, bpV, SCs, and bpV + SCs to 
each other and compared to injury and sham animals. Due to respiratory complications from 
surgery (n = 2) or inadequate contusion injury as recognized by rapid functional recovery (n 
=1), the final animal number for the study was 31 (Sham = 6, Veh = 5, bpV = 5, SCs = 7, 
bpV + SCs = 8). Final impactor displacement of the spinal cord was 2.02 ± 0.21 mm and 
impact velocity was 0.47 ± 0.02 m/s, indicating consistent contusive SCI among 
experimental animals.
For surgical procedures, animals were anaesthetized intraperitoneally (IP) with a ketamine/
xylazine cocktail ([87 mg/kg]/[12 mg/kg]), and received laminectomy only (sham operation) 
or unilateral cervical SCI performed as previously published (Walker et al, 2012). Briefly, 
the 5th cervical vertebra was stabilized with a customized device (Zhang et al., 2004) and a 
partial unilateral laminectomy was performed to expose the right side of the cord. A 
moderate unilateral injury was produced using the NYU/MASCIS Impactor (Gruner, 1992) 
(2.5 mm tip, 10g weight, 12.5 mm height) using previously published methods (Gensel et 
al., 2006; Walker et al., 2012). Sham animals underwent surgery but did not receive injury. 
All animals received subcutaneous injection of 5 mL 0.9% saline for hydration and were 
monitored for 24 hours in housing with controlled temperature. Animals were returned to 
the campus animal housing facility under veterinarian-guided observation and care upon 
recovery. A laboratory animal technician assisted in animal care. All procedures and 
surgeries were approved under the Guide for the Care and Use of Laboratory Animals 
(National Research Council) and the Guidelines of the Indiana University School of 
Medicine Institutional Animal Care and Use Committee.
Intraspinal GFP-SC transplantation
Transplantation of GFP-SCs was slightly modified from previously published methods (Hu 
et al., 2013). Seven to eight days post-injury, GFP-SCs were harvested from culture flasks 
using 0.05% Trypsin-EDTA, washed and suspended in DMEM + 10% FBS on ice for cell 
transplantation. In preparation for transplantation, injured and sham rats were anesthetized 
using ketamine/xylazine and the surgical site was re-opened. Two groups of animals, SCs 
only and bpV + SCs, were designated for SC transplantation into the lesion cavity epicenter. 
The spine was stabilized as described, and cell suspension (1 × 106 GFP-SCs in 5 μl DMEM 
medium) was stereotaxically injected into to lesion epicenter at a depth of 1.2 mm through a 
glass micropipette with an outer diameter of 50–70 μm and beveled sharpened tip at a rate of 
~1 μl/min. After injection, the pipette was left in place for 2 min to prevent cell leakage. 
Animals not receiving SC injection were surgically opened and the sham laminectomy or 
injury site exposed. Following surgery, animals were allowed to recover under conditions 
described for the initial surgical procedures.
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bpV(pic) administration
Groups were randomly designated to receive intraperitoneal (IP) injections of bpV(pic) or 
0.9% saline vehicle according to methods previously described (Walker et al, 2012). Briefly, 
400 μg/kg/day bpV(pic) (Enzo Life Sciences, Inc., Farmingdale, NY) was injected IP 
beginning immediately after injury, 2 hours post-injury, and twice daily for 7 days following 
SCI. Ultimately, two groups received bpV(pic) and the rest, including sham animals, 
received IP injections of saline according to the described treatment schedule.
Behavioral testing
For assessment of forelimb sensorimotor functional recovery, rats were provided flavored 
cereal rings in their home cage prior to and once per week for 11 weeks following injury (10 
weeks after transplantation surgery) and tested as previously described (Walker et al. 2012). 
Briefly, the rats were scored on a 0 to 8 point scale, with 8 being the maximal score, 
according to their ability to support, grasp, and manipulate treats with the injured and non-
injured forelimb while eating the treats. Coordinated treat manipulation was defined as 
obvious consistent coordinated handling of the treat by both forelimbs during eating. Three 
trials (rings) were scored and the average score was presented for each rat during a testing 
session. Two individuals blinded to the animals’ conditions performed the test.
Lesion and spared tissue assessment
Twelve weeks post-injury (11 weeks post-transplantation), all rats were given an overdose 
of ketamine/xylazine and transcardially perfused with 4% paraformaldehyde in 0.1 M PBS. 
Spinal tissue was dissected and processed as previously described (Liu et al., 2006; Walker 
et al., 2012). In brief, a 1 cm segment of cervical cord including the injury epicenter was 
isolated, cryopreserved, and sectioned using a cryostat (Leica) at 20 μm thickness in the 
transverse or longitudinal horizontal planes on Superfrost Plus slides (Fisher Scientific). 
Tissue was kept at −20°C until utilized. Cresyl violet acetate staining with eosin 
counterstaining (CVE) of sectioned tissue was used to aid in identification of the injury 
epicenter. Adjacent sections were processed as previously described for 
immunofluorescence labeling. Briefly, tissues were blocked for non-specific binding of 
antibody and incubated overnight at 4°C with primary antibody against glial fibrillary acidic 
protein (GFAP), a marker of reactive astrocytes and the glial scar (1:200, Sigma). To use a 
clearly defined lesion border, GFAP immunolabeling demarcated the interior and exterior of 
the lesion by the labeling of the glial scar interface. This interface served as the boundaries 
of the lesion, and the area interior to this interface was assessed as a measure of lesion area 
at the epicenter. As the inverse of this value, spared tissue was calculated as all area of the 
ipsilateral cord outside the internal glial scar interface.
Lesion cavity and ventral horn neuron quantification
CVE staining was used to quantify the epicenter cavity area (Fig. 4) and number of ventral 
horn neurons at and 2 mm rostral and caudal to the injury epicenter (Fig. 5). Open cavities 
were traced using contour mapping in Neurolucida software (Microbrightfield, Inc., 
Williston, VT) to obtain cavity area. To quantify spared ventral horn neurons, a horizontal 
line was drawn across the transverse section passing through the central canal to establish a 
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standard anatomical region for analysis. All identifiable ipsilateral neurons ventral to this 
line, exhibiting dark, evenly distributed cresyl violet staining, were manually quantified 
using Neurolucida software.
Quantification of the GFP-SC graft
To provide an estimation of the SC graft relation to the lesion, both GFP-labeling and CVE 
staining of transverse sections were used to identify the graft at the epicenter of injury, 
which corresponded to region of maximal graft area. At the epicenter, SC grafts, if present, 
were traced using contour mapping in Neurolucida for each transplanted animal in the SCs 
group and bpV + SCs group. The average SC graft area per group was determined, and was 
presented as mean absolute graft area at the lesion epicenter. The total area of the graft for 
each animal was also divided by the epicenter section lesion area, which provided a % SC 
graft size of lesion area.
Immunofluorescence labeling
Immunofluorescence double labeling was performed on sections prepared as described 
above and incubated with the following primary antibodies simultaneously with rabbit anti-
GFAP (1:200): mouse anti-SMI31, a marker for axons (1:1000; EMD Millipore, Billerica, 
MA), and mouse anti-rat endothelial cell antigen-1 (RECA-1), a marker for rat vascular 
endothelium (1:200) (ABD Serotec, Inc., Raleigh, NC). The next day, sections were 
incubated with rhodamine-, fluoroisothiocyanate-, or AMCA-conjugated goat anti-rabbit or 
anti-mouse antibodies (1:100, Jackson ImmunoResearch Lab, West Grove, PA). Coverslips 
were mounted on the slides with Fluoromount G (Southern Biotech, Birmingham, AL). Pre-
immune serum was used as a control to confirm the specificity of the antibody. Images were 
obtained with an Olympus BX60 epifluorescent microscope and Neurolucida software 
(Microbrightfield, Inc.).
Statistical Analysis
A two-tailed unpaired Student’s t-test was used to determine statistical significance between 
two groups. Statistical significance between multiple groups was determined using a one-
way ANOVA with post-hoc analysis if significance was established. For functional 
assessment and comparison between groups over time, a repeated-measures ANOVA was 
performed followed by Tukey’s post-hoc analysis. All statistics were calculated using 
GraphPad Prism 5.0 software (GraphPad, Inc., La Jolla, CA), with a p value < 0.05 
considered statistically significant.
Results
bpV and bpV + SCs significantly improved forelimb function
To test the recovery of sensorimotor function, a cereal ring treat-handling test was 
performed for 10 weeks post-transplantation. Throughout testing, all groups performed 
dependably with an overall trend in improvement (Fig. 2). A repeated-measures ANOVA 
showed significant treatment effects on scoring throughout the study (F [4, 26] = 21, p< 
0.0001). At Week 10, only animals in the bpV (p < 0.05) and bpV + SCs (p < 0.01) 
treatment groups scored significantly higher than saline-treated (Vehicle) controls. No 
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statistical significance was observed between bpV and SCs, bpV and bpV + SCs, or SCs and 
bpV + SCs treatment groups at the end of testing; however, at least once during the testing 
period all groups exhibited significantly improved scores over vehicle-only treated animals 
(Fig. 2).
bpV and bpV + SCs significantly reduced lesion and cavitation, and increased spared 
tissue and ventral horn neurons
As a measure of neuroprotection, lesion area, spared tissue, and cavity size were calculated. 
At the conclusion of the study, tissue from both bpV and bpV + SCs groups showed 
significantly reduced lesion area and increased spared tissue area (p < 0.01 & p < 0.05, 
respectively; Fig. 3F&G). The bpV treatment groups also showed significantly reduced 
lesion area and increased spared tissue over the SC transplantation group (p < 0.05; Fig. 
3F&G). Decreased lesion area highly correlated with improved functional assessment scores 
(R2 = 0.93) (Fig. 3H). Lesion cavity area was significantly reduced in all treated animals 
(bpV and bpV + SCs, p < 0.01; SCs only, p < 0.05) compared to the Vehicle control animals 
(Fig. 4A–E); however, no significant difference was observed between the treatment groups. 
Similar to the trend observed for lesion and cavity reduction and overall tissue sparing, both 
bpV and bpV + SCs treatments promoted significant ventral horn neuron sparing compared 
to the Vehicle treatment (p < 0.05; Fig. 5A & B), though only 2.0 mm caudal to the injury 
epicenter. A similar trend was observed 2.0 mm rostral to the epicenter, but the difference 
was not statistically significant. Almost no neurons were observed at the injury epicenter in 
any group.
Influence of SC graft area on lesion reduction in SC and bpV + SC groups
SC graft area was outlined and quantified at the lesion epicenter. Results showed that total 
SC graft area is similar between SC only and the bpV + SCs treatment groups (Fig. 6E). 
However, as the lesion area affects and may be influenced by the graft, to best compare the 
graft size between both groups was to divide the cross-sectional area of the SC graft at the 
epicenter by the area of the lesion for that animal. This revealed a much different 
comparison, showing a greater graft-to-lesion ratio in the bpV + SCs group compared to SC 
transplantation only; however, this difference was not statistically significant (Fig. 6F). 
However, whether the SC transplantation enhanced lesion reduction or the lesion in which 
the graft was initially injected was smaller cannot be determined from these data. 
Nonetheless, functional assessment results suggest bpV may mediate significant 
neuroprotection and lesion reduction within the first week post-injury. Also, both bpV and 
bpV + SC groups show similar lesion reduction ability which suggests bpV may have 
already reduced the lesion cavity before SCs were transplanted, resulting in the observed 
trend in increased graft-to-lesion ratio.
Axonal and vascular growth within the SC grafts
To determine whether GFP-SC grafts promoted ingrowth of axons and vasculature, 
immunofluorescent staining of SMI-31 and RECA-1, respectively, at the center of graft was 
examined (Fig. 7). Animals received no SC transplantation were served as controls. As 
shown in Fig. 7C, non-transplanted rats exhibited little to no SMI-31+ axons within the 
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boundaries of GFAP. In contrast, SC transplantation only (Fig. 7G) and bpV + SCs (Fig. 
7K) groups promoted remarkable axonal growth into the SC graft. Overall, total axonal area 
within the graft (Fig. 7M) and axonal area as a percentage of maximal graft area (Fig. 7N) 
was similar between the two transplantation groups. Nonetheless, as bpV + SCs promoted a 
higher graft-to-lesion ratio, a significant increase of 89 ± 20% of SMI-31+ axons over SCs 
only as a ratio of axons to lesion size (Fig. 7O). Likewise, lack of vascular presence in the 
lesion cavity was found in non-transplanted animals (Fig. 8A & A′). In contrast, evident of 
vascular ingrowth into the graft region at the lesion site was found in the SC only (Fig. 8B & 
B′) and bpV + SCs groups (Fig. 8C & C′). Like axonal presence in the graft, vasculature was 
similarly distributed between the two SC-transplanted groups.
Discussion
bpV alone or combined with SC transplantation promoted significant forelimb function 
recovery and neuroprotection
In the present study, we show that bpV promotes neuroprotection and functional recovery, 
and that these benefits are similar to those provided by the combination of bpV and SCs. 
This evidence confirms bpV as a valuable therapy for improving functional recovery, which 
is likely closely tied to its neuroprotective effects. When transplanted alone, SCs did not 
significantly improve forelimb functional ability at the end of the study (Fig. 2), but showed 
remarkable survival throughout the nearly 3 month long study (Fig. 6). In a recent report, we 
showed that SCs isolated from this transgenic GFP-expressing SD rat strain showed 
proliferative and considerable survival potential as assessed through 1 year post-
transplantation in a contusive SCI lesion produced in SD rats (Wang and Xu, 2014). As SD 
rats are outbred rats, this recent study involved long-term administration of the 
immunosuppressant cyclosporin A to repress potential rejection of the SC graft by the rats. 
As administering cyclosporin A could affect the pharmacologic effects of bpV utilized in 
our study, we did not use cyclosporin in any animals in the present study. Upon final 
histological assessment, we observed relatively healthy SC grafts in nearly all of the 
transplanted rats (7 of 9). These results suggest that the GFP-SCs survived for 
approximately three months in SD rats without the use of immunosuppressant therapy in the 
current study.
Although SCs were identifiable in animals transplanted with SCs or bpV + SCs, treatment 
with bpV, regardless of subsequent SC transplantation, promoted greater functional recovery 
over SCs alone. Even still, there was no distinct evidence or observation that bpV directly 
affected the SC graft or that it influenced host tissue interaction with the transplanted SCs. 
The SCs, however, play a unique role in providing permissive substrate for axonal growth 
and revascularization through the injury site. We cannot determine whether SCs definitively 
contributed to recovery of forelimb function based on our data presented here. As we only 
used one behavioral assessment for forelimb recovery, this test may not be sensitive for 
detection of recovery following SC transplantation. Alternatively, SCs alone may not be 
sufficient to meaningfully increase forelimb recovery as suggested in other studies. Thus, 
developing new repair strategies combining SC transplantation and other efficacious 
strategies such as the use of bpV acute neuroprotection may enhance functional recovery.
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Based on functional assessment results, bpV’s effect on function recovery is maintained 
over the course of both 6 (Walker et al., 2012) and 11 weeks post-SCI. Further affirming 
these results, the combination therapy showed very similar neuroprotective effects, as well 
as sustained improvement in functional outcome over the course of this study. SC 
transplantation alone did not promote significant neuroprotection compared to the Vehicle 
group (Fig. 3). In addition, behavioral assessment scores inversely correlated with lesion 
area (Fig. 3H). Nevertheless, our findings suggest bpV may have played a more important 
role in neuroprotection and functional recovery than SC transplantation. Also, both bpV and 
bpV + SC groups showed similar lesion reduction ability which raises the possibility that 
bpV may have already reduced the lesion before SCs were transplanted. Despite not having 
cells transplanted into the lesion, bpV exhibited similar lesion cavity reduction to both the 
SCs and bpV + SCs treatment groups, further supporting this interpretation. In continuation 
of the beneficial influence of bpV on neuroprotection, only bpV and bpV + SCs groups 
showed significant ventral horn neuron sparing caudal to the injury, and a similar trend 
rostrally (Fig. 5).
Influence of bpV on SCs and host axon growth into the lesion
Although the total area of the SC graft at the epicenter was similar between groups (1.88 × 
105 ± 6.3 × 104 vs. 1.87 × 105 ± 5.4 × 104 μm2; Fig. 6E), the graft-to-lesion ratio was higher 
in the combination group compared to animals that received only SC transplantation (Fig. 
6E & F). Reduced lesion area promoted by acute bpV treatment resulted in a somewhat 
greater graft-to-lesion ratio (Fig. 6F), which may have contributed to a significantly higher 
axon/lesion area value (Fig. 7D). However, no statistically significant differences were 
observed between the SC and bpV + SC treatment groups concerning graft/lesion ratio. 
When investigating axonal presence within the lesion in non-grafted animals (Fig. 7A), 
almost no axons were observed inside the GFAP boundaries of the lesion. Using SCs as a 
lone therapy, Schaal and colleagues transplanted cells into the contused cervical spinal cord 
and observed supraspinal axonal growth into the graft, as well as SC-mediated forelimb 
functional recovery (Schaal et al., 2007). In 2008, one group loaded SCs into poly-β-
hydroxybutyrate (PBH) channels, implanted the graft into the hemisected gap, and identified 
serotonergic raphespinal and calcitonin gene-related peptide (CGRP) fibers, but not 
descending motor rubrospinal axons within the graft (Novikova et al., 2008). Although we 
observed axonal growth into the graft, our study did not assess the origin of these axons. As 
no significant difference in functional improvement was observed between bpV-treated and 
bpV + SCs treated animals, the significant axonal occupation within the lesion may have 
been incidental to the reduced lesion area concerning effects on functional recovery.
SCs promoted vascular ingrowth
A similar pattern was observed for RECA-1+ vasculature. In both transplant groups, SC 
transplantation promoted clear vascular growth at the epicenter of the graft (Fig. 8B–C′), 
while negligible vasculature was observed in the lesions of non-SC transplanted animals 
(Fig. 8A & A′). To our knowledge, this study is the first to report vascular growth into the 
SC graft in a cervical SCI model. The exact mechanism influencing vascular generation, or 
the influence these vessels imparted on the grafted SCs or axonal ingrowth in this model is 
unclear. Evidence suggests angiogenesis is beneficial following SCI (Han et al., 2010), and 
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can promote axonal sprouting and growth (Dray et al., 2009; Loy et al., 2001), all findings 
that support the results observed in the present study. Although both SCs and bpV + SC 
transplantation groups exhibited vascular labeling within the SC graft, we do not have 
sufficient evidence to determine whether the combination strategy was better at promoting 
vascularization of the graft than SC transplantation alone. Further analysis of vascular 
growth in the graft will help identify whether these vessels are functional, and whether their 
effects contribute benefits to the grafted cells or surrounding host tissue.
Association between treatment and functional recovery
What potentially contributed to the functional improvement in the bpV and bpV + SCs 
groups based on our histological findings? This outcome could have resulted from both gray 
and white matter sparing in these groups as both treatments promoted significantly reduced 
lesion areas and increased overall spared tissue at the lesion epicenter, a measure that 
significantly correlates with lesion severity and behavioral analysis outcomes following 
contusive SCI (Bresnahan et al., 1987; Noble and Wrathall, 1985). However, as all injured 
animals failed to fully extend and grasp the treats with the digits suggests chronic 
corticospinal tract damage in the ipsilateral dorsal column. Therefore, further analysis of 
bpV’s effects on this tract could help shed light on mechanisms to target CST protection and 
repair to further improve the rats’ ability to perform the treat manipulation exercise.
In a thoracic contusive SCI, SCs have demonstrated the ability to enhance Basso, Beattie, 
and Bresnahan (BBB) (Basso et al., 1995) hindlimb locomotor scores (Barakat et al., 2005; 
Takami et al., 2002). Conversely, Pearse and colleagues showed no benefit in BBB scoring 
for animals transplanted only with SCs over injury alone, although SCs could significantly 
improve hindpaw rotation in footprint analysis (Pearse et al., 2004a; Pearse et al., 2007). 
Evidence suggests SCs are more effective for repair than other cell types for transplantation, 
such as olfactory ensheathing cells or glia (OECs or OEGs) for treating experimental 
contusive SCI (Takami et al., 2002); however, in most studies, combining SCs with other 
therapies or genetically-modifying SCs promotes more notable recovery in rat behavioral 
assessments than SCs alone even when SCs exhibit a benefit. In one recent study, injured 
animals grafted with SCs genetically modified to overexpress the neurotrophic factor GDNF 
showed improved locomotor recovery over SCs alone (Deng et al., 2013). These mixed 
results suggest that although SCs promote positive results as a therapy for SCI, their effects 
may not be sufficient for recovery unless other therapies are combined. Our recent research 
supports this notion, as SC transplantation did not improve BBB scores or footfall errors 
over control animals (Wang and Xu, 2014). Various objective measures of gait during 
locomotion also showed no significant difference compared to controls. We did observe 
incredible survival capability of the transplanted SCs, however, which should inspire 
continued optimism in the use of SC transplantation in combined therapies.
Biphasic versus overlapping combination therapy
Remarkably few studies have been reported on SC transplantation at the cervical level, 
however, those that were performed focused on combining SCs with an additional treatment 
or strategy to produce host and SC graft effects. Our study continues this trend with the 
biphasic combination treatment of acute bpV and subacute SC transplantation. The most 
Walker et al. Page 10
Exp Neurol. Author manuscript; available in PMC 2016 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
comparable study of the cervical SC transplantation studies investigated a co-treatment of 
17β-estradiol with transplantation of SCs into the hemi-contused cervical spinal cord 
(Siriphorn et al., 2010). In this study, a 17β-estradiol (E2) pellet (5 mg/pellet, 21-day 
continuous release) was implanted subcutaneously 30 min following injury. After a delay of 
8 days post-SCI, 5-(and-6)-carboxyfluoreceindiacetatesuccinimidyl ester (CFSE)-labeled 
SCs were transplanted into the contusion site and animals were allowed to survive for 7 days 
following transplantation. The overlapping administration of 17β-estradiol and SC 
transplantation, aimed at testing E2 effects on SC survival, is interesting and yielded novel 
information. In our case, we examined a two-phase treatment regimen with bpV(pic) 
administration and SC transplantation to determine whether the biphasic treatments lead to 
synergistic effects. We are investigating potential effects of bpV on SCs in vitro to address 
this possibility, as well as other potential combination benefits of bpV and SCs for SCI.
Conclusion
Ultimately, the results of this study suggest bpV likely promoted most of the neuroprotective 
benefits, and played a larger role in functional recovery than SC transplantation when the 
two therapies were combined. Transplanted SCs elicited a dynamic host tissue response, 
promoting considerable axonal and vascular ingrowth over the course of the study. The 
impact of these responses on recovery, however, is indeterminable from the observed 
results. The vasculature observed in the graft, if functional, could have provided nutrients 
and growth components necessary for long-term SC survival and axon growth. The bpV 
component of our combination therapy possibly enhanced recovery through acute sparing of 
neurons and other cells from secondary damage following SCI. If combined with another 
treatment to degrade the glial scar or allow SC overexpression of trophic factors, 
transplantation of SCs may contribute more substantially to neuroprotection, axonal growth 
into caudal host tissue, and forelimb functional recovery. Future studies will address these 
and other issues concerning the potential of SCs in combination therapies following SCI.
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Highlights
• Schwann cells (SCs) are a promising candidate for cell therapy after spinal cord 
injury
• However, Schwann cells have limitations when used alone
• Bisperoxovanadium (bpV) compound is a promising neuroprotective agent
• Combining bpV with SC transplantation enhanced neuroprotection and recovery
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Figure 1. Experimental design and treatments for the bpV(pic)/GFP-SC combination study
(A) Time course and milestones of the experiment. (B) The structure of bpV(pic). (C) A 
photomicrograph of confluent pure GFP-SCs used for transplantation. Scale bar = 200 μm.
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Figure 2. Forelimb sensorimotor assessment scores
Rats were tested on coordinated forelimb movement and manipulation of cereal rings during 
eating. Post-SCI behavior was performed 1 week after SCI and just before the 2nd surgery. 
At the end of the study bpV + SCs and bpV-only group scores were significantly higher than 
the Vehicle group. bpV + SCs, *, p< 0.05 vs. Veh; ** p< 0.01 vs. Veh; *** p< 0.001 vs. 
Veh. bpV, #, p< 0.05 vs. Veh; ## p< 0.01 vs. Veh; ### p< 0.001 vs. Veh. SCs, $, p< 0.05 vs. 
Veh; $$, p< 0.01 vs. Veh; $$$ p< 0.001 vs. Veh.
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Figure 3. bpV and bpV + SCs reduced lesion and enhanced spared tissue
(A) Schematic drawing illustrated how lesion and spared issue are defined. (B–E) GFAP 
immunostaining clearly defined astrocytic glial boarder around the lesion in all groups. 
Marked reduction of lesion was found in bpV and bpV + SCs treatment groups. (F and G) 
Significant reduction of percent lesion area (F) and increase in percent spared tissue (G) 
were found as compared to Vehicle-treated group. Animals treated with SCs alone exhibited 
a trend in neuroprotective measures, but showed no statistical significance compared to the 
Vehicle group. (H) Lesion reduction closely correlated with the mean functional scores of 
each group (R2 = 0.93). *, p < 0.05. Scale bar = 1 mm. Bars = mean ± SEM.
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Figure 4. bpV, SCs, used alone or in combination, reduced lesion cavity
(A–D) Cresyl violet/eosin (CVE) staining shows cavities at the lesion epicenter in different 
groups. All three bpV and/or SC treatment groups (B–D) showed marked reduction of lesion 
cavities as compared to the Vehicle-treated control (A). (E) The three treatment groups 
showed statistically significant reduction of lesion cavitation as compared to the Vehicle 
group, although no difference was found between these treatment groups. *, p< 0.05; **, p< 
0.01. Scale bar = 1 mm.
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Figure 5. bpV and bpV + SCs increased the number of ventral horn neurons adjacent to the 
epicenter of injury
(A) Cresyl violet/eosin-stained cross sections cut at 2mm rostral, epicenter, and 2 mm caudal 
to the injury in groups received different treatments. Ventral horn neurons were clearly seen 
(right column). (B) Only bpV and bpV + SCs groups significantly increased the number of 
ventral horn neurons at 2 mm caudal to the lesion. *, p< 0.05. Scale bar: 2 mm rostral & 
epicenter = 1mm; 2mm caudal = 250 μm.
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Figure 6. Comparison of GFP-SC graft area between SCs and bpV + SCs groups
(A–D) SCs in both transplantation groups (C and D) but not in the Vehicle (A) or bpV (B) 
group showed GFP labeling in the lesion, indicating the survival of the grafted SCs. (E) 
Areas occupied by grafted GFP-SCs was similar between the SCs and bpV + SCs groups. 
(F) bpV + SCs exhibited greater GFP-SC/Lesion Area ratio than animals receiving SC 
transplantation alone although the difference was not statistically significant. Scale bar = 1 
mm.
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Figure 7. SC transplantation promoted axonal growth within the lesion
(A–L) High power cross-section view of the ipsilateral lesion epicenter in the Vehicle, SCs, 
and bpV-SCs groups. (A–D) In the Vehicle control group receiving no SC transplantation, 
no axonal growth into the lesion was found. (E–L) In groups that receiving SCs (E–H) or 
bpV-SC (I–L), considerable axonal growth, immunolabeled by SMI-31, into the lesion site 
was found (G, K) and they were closely associated with grafted GFP-SCs (F–J). (M–O) 
There was no statistically significance difference between the total SMI-31+ area (M), nor 
SMI-31+ as a fraction of SC-graft area (N). However, axonal growth into the graft as an 
index of lesion size was significantly greater in the bpV-SC treatment group as compared 
with the SCs only group (O). *, p < 0.05. Scale bar = 750 μm.
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Figure 8. SCs promoted vascular growth into the graft
(A–A′) In the Vehicle control group receiving no SC transplantation, no RECA-1+ 
vasculature was found within the lesion. (B–C′) RECA-1+ vascular growth into the GFP-SC 
grafts was clearly seen in groups receiving SCs (B–B′) and bpV + SCs (C–C′). White 
arrowheads indicate RECA-1+ blood vessels. Scale bar = 1 mm (A), 500 μm (B & B′), 50 
μm (C & C′).
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